Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens

Rubraca Revenues Are Shrinking

Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.

Downward red arrow concept

Clovis Oncology has warned it is “increasingly probable” that it will enter bankruptcy as revenues shrink and the regulatory outlook worsens for its only marketed drug, Rubraca.

The Bolder, CO-based specialist pharma company has been struggling for years to gain traction with Rubraca (rucaparib), the least favoured...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip